Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?

被引:32
作者
Shalini [1 ]
Kumar, Vipan [1 ]
机构
[1] Guru Nanak Dev Univ, Dept Chem, Amritsar, Punjab, India
关键词
Cancer; hybrid molecules; drug design; structure-activity relationship; clinical trials; approved drugs; HISTONE DEACETYLASE INHIBITORS; CELL-CYCLE ARREST; BIOLOGICAL EVALUATION; HYDROXAMIC ACIDS; BREFELDIN-A; ANTIPROLIFERATIVE EVALUATION; DERIVATIVES SYNTHESIS; ANTITUMOR-ACTIVITY; NITROGEN MUSTARDS; TOPOISOMERASE-II;
D O I
10.1080/17460441.2021.1850686
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Cancer continues to be a big threat and its treatment is a huge challenge among the medical fraternity. Conventional anti-cancer agents are losing their efficiency which highlights the need to introduce new anti-cancer entities for treating this complex disease. A hybrid molecule has a tendency to act through varied modes of action on multiple targets at a given time. Thus, there is the significant scope with hybrid compounds to tackle the existing limitations of cancer chemotherapy. Area Covered This perspective describes the most significant hybrids that spring hope in the field of cancer chemotherapy. Several hybrids with anti-proliferative/anti-tumor properties currently approved or in clinical development are outlined, along with a description of their mechanism of action and identified drug targets. Expert opinion The success of molecular hybridization in cancer chemotherapy is quite evident by the number of molecules entering into clinical trials and/or have entered the drug market over the past decade. Indeed, the recent advancements and co-ordinations in the interface between chemistry, biology, and pharmacology will help further the advancement of hybrid chemotherapeutics in the future.
引用
收藏
页码:335 / 363
页数:29
相关论文
共 152 条
[1]   HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination [J].
Adimoolam, Shanthi ;
Sirisawad, Mint ;
Chen, Jun ;
Thiemann, Patti ;
Ford, James M. ;
Buggy, Joseph J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (49) :19482-19487
[2]   A review on anticancer potential of bioactive heterocycle quinoline [J].
Afzal, Obaid ;
Kumar, Suresh ;
Haider, Md Rafi ;
Ali, Md Rahmat ;
Kumar, Rajiv ;
Jaggi, Manu ;
Bawa, Sandhya .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 97 :871-910
[3]   An overview of quinazolines: Pharmacological significance and recent developments [J].
Alagarsamy, V. ;
Chitra, K. ;
Saravanan, G. ;
Solomon, V. Raja ;
Sulthana, M. T. ;
Narendhar, B. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 151 :628-685
[4]   Synthesis and anticancer activity of brefeldin A ester derivatives [J].
Anadu, Nwanne O. ;
Davisson, V. Jo ;
Cushman, Mark .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (13) :3897-3905
[5]   The Ocean Reanalyses Intercomparison Project (ORA-IP) [J].
Balmaseda, M. A. ;
Hernandez, F. ;
Storto, A. ;
Palmer, M. D. ;
Alves, O. ;
Shi, L. ;
Smith, G. C. ;
Toyoda, T. ;
Valdivieso, M. ;
Barnier, B. ;
Behringer, D. ;
Boyer, T. ;
Chang, Y-S. ;
Chepurin, G. A. ;
Ferry, N. ;
Forget, G. ;
Fujii, Y. ;
Good, S. ;
Guinehut, S. ;
Haines, K. ;
Ishikawa, Y. ;
Keeley, S. ;
Koehl, A. ;
Lee, T. ;
Martin, M. J. ;
Masina, S. ;
Masuda, S. ;
Meyssignac, B. ;
Mogensen, K. ;
Parent, L. ;
Peterson, K. A. ;
Tang, Y. M. ;
Yin, Y. ;
Vernieres, G. ;
Wang, X. ;
Waters, J. ;
Wedd, R. ;
Wang, O. ;
Xue, Y. ;
Chevallier, M. ;
Lemieux, J-F. ;
Dupont, F. ;
Kuragano, T. ;
Kamachi, M. ;
Awaji, T. ;
Caltabiano, A. ;
Wilmer-Becker, K. ;
Gaillard, F. .
JOURNAL OF OPERATIONAL OCEANOGRAPHY, 2015, 8 :S80-S97
[6]   Histone Acetylation-Mediated Regulation of the Hippo Pathway [J].
Basu, Dipanjan ;
Reyes-Mugica, Miguel ;
Rebbaa, Abdelhadi .
PLOS ONE, 2013, 8 (05)
[7]   E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models [J].
Bello, Ezia ;
Colella, Gennaro ;
Scarlato, Valentina ;
Oliva, Paolo ;
Berndt, Alexander ;
Valbusa, Giovanni ;
Serra, Sonia Colombo ;
D'Incalci, Maurizio ;
Cavalletti, Ennio ;
Giavazzi, Raffaella ;
Damia, Giovanna ;
Camboni, Gabriella .
CANCER RESEARCH, 2011, 71 (04) :1396-1405
[8]   Aminosuberoyl hydroxamic acids (ASHAs): A potent new class of HDAC inhibitors [J].
Belvedere, Sandro ;
Witter, David J. ;
Yan, Jiaming ;
Secrist, J. Paul ;
Richon, Victoria ;
Miller, Thomas A. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (14) :3969-3971
[9]   PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells [J].
Bhalla, Savita ;
Balasubramanian, Sriram ;
David, Kevin ;
Sirisawad, Mint ;
Buggy, Joseph ;
Mauro, Lauren ;
Prachand, Sheila ;
Miller, Richard ;
Gordon, Leo I. ;
Evens, Andrew M. .
CLINICAL CANCER RESEARCH, 2009, 15 (10) :3354-3365
[10]   Development of broad spectrum mycosporine loaded sunscreen formulation from Ulva fasciata delile [J].
Bhatia, Saurabh ;
Sardana, Satish ;
Sharma, Ajay ;
Vargas De La Cruz, Celia Bertha ;
Chaugule, Bhupal ;
Khodaie, Laleh .
BIOMEDICINE-TAIWAN, 2019, 9 (03) :12-18